Ruud H Brakenhoff
Overview
Explore the profile of Ruud H Brakenhoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
6699
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beddok A, Velleuer E, Sicre de Fontbrune F, Brakenhoff R, Dalle J, Dufour C, et al.
Cancer Lett
. 2025 Mar;
617:217529.
PMID: 40054658
Fanconi Anemia (FA) is an inherited disorder associated with profound DNA repair defects, marked by failure to thrive, congenital malformations, progressive bone marrow failure (BMF), and an increased susceptibility to...
2.
Muijlwijk T, Nauta I, van der Lee A, Grunewald K, Brink A, Ganzevles S, et al.
Nat Commun
. 2025 Feb;
16(1):1705.
PMID: 39962066
No abstract available.
3.
Lenoci D, Serafini M, Lucchetta M, Cavalieri S, Brakenhoff R, Hoebers F, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941896
Background: Despite advances in the management of head and neck squamous cell carcinoma (HNSCC), prognostic models and treatment strategies remain inadequate, particularly for HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The...
4.
Jansen F, Eerenstein S, Arman S, Lissenberg-Witte B, Hardillo J, Takes R, et al.
JAMA Otolaryngol Head Neck Surg
. 2025 Feb;
PMID: 39913126
Importance: Adverse effects of cancer and its treatment may hamper return to work (RTW) among patients with head and neck cancer (HNC). Objectives: To investigate RTW among patients with HNC...
5.
Stoof J, Kalmoua Z, Sobota A, Brakenhoff R, Stigter M, Pham T, et al.
Sci Rep
. 2025 Jan;
15(1):2334.
PMID: 39824909
Bladder cancer often recurs, necessitating innovative treatments to reduce recurrence. We investigated non-thermal plasma's potential as a novel anti-cancer therapy, focusing on plasma-activated solution (PAS), created by exposing saline to...
6.
Nauta I, Nijenhuis D, Ganzevles S, Raaff P, Kloosterman J, Bloemena E, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796740
Background/objectives: Most studies on the interaction between the immune system and cancer focus on T-cells, whereas studies on tumor-infiltrating B-lymphocytes (TIL-Bs) are still underrepresented. The aim of this study was...
7.
Muijlwijk T, Nauta I, van der Lee A, Grunewald K, Brink A, Ganzevles S, et al.
Nat Commun
. 2024 Oct;
15(1):9060.
PMID: 39428388
Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs). Besides mutations, these copy number changes are key characteristics of cancer development. Nonetheless, some tumors show...
8.
von Buchwald C, Jakobsen K, Fenger Carlander A, Tous S, Gronhoj C, Rasmussen J, et al.
Eur J Cancer
. 2024 Sep;
211:114329.
PMID: 39293346
Purpose: The assessment of p16INK4a (p16) in oropharyngeal squamous cell carcinoma (OPSCC) has been incorporated into tumor classification, as p16 has been shown to impact survival probability. However, a recent...
9.
Muijlwijk T, Wondergem N, Ekhlas F, Remkes N, Nijenhuis D, Fritz L, et al.
Cancer Immunol Immunother
. 2024 Sep;
73(11):229.
PMID: 39249543
Immune checkpoint inhibitors are approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) but the response rate is only 13-18%. For an effective antitumor immune response, trafficking of immune...
10.
Muijlwijk T, Nijenhuis D, Ganzevles S, Ekhlas F, Ballesteros-Merino C, Peferoen L, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 39053947
Background: Approximately 50% of head and neck squamous cell carcinomas (HNSCC) recur after treatment with curative intent. Immune checkpoint inhibitors are treatment options for recurrent/metastatic HNSCC; however, less than 20%...